These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21971583)

  • 1. Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.
    Yoshida K; Nagai T; Ohmine K; Uesawa M; Sripayap P; Ishida Y; Ozawa K
    Biochem Pharmacol; 2011 Dec; 82(12):1884-90. PubMed ID: 21971583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.
    Pirker C; Lötsch D; Spiegl-Kreinecker S; Jantscher F; Sutterlüty H; Micksche M; Grusch M; Berger W
    Exp Dermatol; 2010 Dec; 19(12):1040-7. PubMed ID: 21087322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
    Fu S; Li Y; Huang J; Liu T; Hong Z; Chen A; Bast RC; Kavanagh JJ; Gershenson DM; Sood AK; Hu W
    Cancer Biol Ther; 2012 Sep; 13(11):1034-41. PubMed ID: 22895067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.
    Huang XF; Luo SK; Xu J; Li J; Xu DR; Wang LH; Yan M; Wang XR; Wan XB; Zheng FM; Zeng YX; Liu Q
    Blood; 2008 Mar; 111(5):2854-65. PubMed ID: 18160664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
    Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
    Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Walsby E; Walsh V; Pepper C; Burnett A; Mills K
    Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.
    Xu DR; Huang S; Long ZJ; Chen JJ; Zou ZZ; Li J; Lin DJ; Liu Q
    J Transl Med; 2011 May; 9():74. PubMed ID: 21600017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3.
    Amico D; Barbui AM; Erba E; Rambaldi A; Introna M; Golay J
    Blood; 2003 Jun; 101(11):4589-97. PubMed ID: 12576328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
    Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
    Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.
    de Paula Careta F; Gobessi S; Panepucci RA; Bojnik E; Morato de Oliveira F; Mazza Matos D; Falcão RP; Laurenti L; Zago MA; Efremov DG
    Haematologica; 2012 Aug; 97(8):1246-54. PubMed ID: 22331265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
    Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Aurora B kinase in non-Hodgkin lymphoma.
    Ikezoe T; Takeuchi T; Yang J; Adachi Y; Nishioka C; Furihata M; Koeffler HP; Yokoyama A
    Lab Invest; 2009 Dec; 89(12):1364-73. PubMed ID: 19823168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
    Okabe S; Tauchi T; Ohyashiki K
    Ann Hematol; 2010 Nov; 89(11):1081-7. PubMed ID: 20563869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.